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Abstract 
There is increasing evidence that menopausal changes can have an impact on women’s 
cognition and potentially, the future development of dementia. In particular, the role of 
reduced levels of oestrogen in postmenopausal changes has been linked to an increased risk 
of developing dementia in observational studies. Not surprisingly, this has led to several 
clinical trials investigating whether postmenopausal hormone replacement therapy (HRT) can 
potentially delay/ avoid cognitive changes and subsequently, the onset of dementia. However, 
the evidence of these trials has been mixed, with some showing positive effects while others 
show no or even negative effects. In the current review, we investigate this controversy 
further by reviewing the existing studies and trials in cognition and dementia.  Based on the 
current evidence, we conclude that previous approaches may have used a mixture of women 
with different genetic risk factors for dementia which might explain these contradicting 
findings. Therefore, it is recommended that future interventional studies take a more 
personalised approach towards HRT use in postmenopausal women, by taking into account 
the women’s genetic status for dementia risk.  
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Introduction 
Dementia is one of the most prevalent diseases for ageing societies worldwide. According to 
the World Health Organisation report (2015), 47.5 million people worldwide have dementia 
and there are 7.7 million new cases annually. 1 Historically, dementia has been seen as a 
disease of old age, with age being the greatest risk factor for dementia. 2,3,4 However, recent 
evidence suggests that pathophysiological changes leading to dementia can occur up to 20 
years before the presentation of clinical symptoms 5,6, which has stimulated an urgent need to 
investigate how several demographic and life-course factors influence the risk of 
pathologically-induced cognitive decline. 3 In particular, sex-related differences in neural 
anatomy is emerging as an important factor for both the development and treatment of 
dementia. 2,7 
 
The risk for dementia appears to differ for men and women throughout the ageing process 8, 
with women showing an increased risk for dementia shortly after menopause. 9 These 
findings dovetail with women commonly reporting a ‘brain fog’ descending after menopause, 
which might be the first indication of increased dementia risk. 7,10 Nonetheless, the 
relationship of menopause induced cognitive changes and risk of dementia is still under 
exploration, with previous studies offering conflicting findings to date. The aim of this 
review is to explore the literature investigating the link between menopause, cognition, and 
dementia. In this review, we will firstly highlight the current evidence for the relationship 
between cognition and menopause before exploring the evidence for an association between 
dementia and menopause. We conclude by outlining potential future directions based on the 
reviewed evidence.  
 
Cognition and menopause 
The occurrence of cognitive changes during menopause is clinically a very common 
observation, with many subjective reports of ‘brain fog’ during the menopausal transition, 
affecting cognitive performance in everyday life. 11 In particular, individuals suffer from 
impairments to their attention, processing speed and memory, which subsequently manifest as 
lack of focus, sluggishness and forgetfulness as some of the most common symptoms. 10,12 
For example, cross-sectional findings from the Study of Women’s Health Across the Nation 
(SWAN) in a large cohort of women (n=16,065) aged between 40-55 years showed that 31% 
of premenopausal women reported increased forgetfulness which increased to 41% in 
postmenopausal women 13,14 although the contribution of other demographic and lifestyle 
factors on cognitive performance was not explored. Longitudinal studies have corroborated 
these cross-sectional changes in cognition, with women reporting worsening cognitive 
performance from pre- to post-menopause. 12,15,16 Importantly, these subjective reports of 
altered cognitive performance were further supported by more objective cognitive testing, 
which have shown that premenopausal women perform better than postmenopausal women 
on neuropsychological testing, 17 although the sample sizes for such studies are too limited to 
draw any definite conclusions at this stage.  
 
The reported cognitive changes during menopause have implicated a potential role for 
hormones (in particular, oestrogen) on cognition. 15,18 Specifically, changes in the levels of 
oestrogen as well as expression of oestrogen receptor genes (e.g. ESR1, ESR2) have been 
shown to have an effect on cognition during menopausal transition 10,11 and ageing 
respectively. 19,20 This should be not surprising as oestrogen is well known to have strong 
effects on brain function and integrity, in addition to its reproductive function. For example, 
oestrogen has been shown to have a key role in regulating glucose metabolism in the brain. 21 
Glucose metabolism is directly linked to improved cognition, hence a reduction in the 
provision and potential uptake of glucose in the brain as a result of lower oestrogen levels 
might partially account for the observed changes in cognitive performance post-menopause. 
21,22 Similarly, oestrogen has been shown to have significant neurotrophic factors, 23,24 
therefore impacting on neurogenesis and homeostatic brain function, 25 which further 
highlights the role of this female sex hormone in brain health.  
 
Most importantly, oestrogen also functions in the metabolism of acetylcholine, one of the 
main neurotransmitters critical for attention and memory processes. 26 Hence the deficits, 
specifically in attention and memory, post-menopause might potentially be linked to this 
hormonal-neurotransmitter transaction, although such interactions have to date only been 
shown in animal models 25 Clearly, future investigations exploring this role of oestrogen 
towards acetylcholine and cognition, in particular on a longitudinal level, are needed to 
determine the dynamics of the genotypic and neurotransmitter interactions  over long time 
periods.  
On a more mechanistic level, several clinical trials involving hormone replacement therapies 
(HRT) in postmenopausal women have examined cognitive performance as a secondary 
outcome measure. 27,28,29 However, the results from these trials have so far been inconsistent, 
with some trials showing beneficial effects for cognitive performance, whilst others show no 
or even deleterious effects on cognitive performance in postmenopausal women. 30,31,32,33 
These findings have led to the emergence of a ‘critical window’ hypothesis 12, which states 
that the HRT can have a positive impact on cognition in pre- and perimenopausal women (up 
until the age of 60 year when dementia risk is small), but might have a negative effect on 
cognition in postmenopausal women (see also dementia section below). 34 However, it should 
be noted that null/negative effects of HRT on female cognition are observed particularly 
among women with a heightened genetic vulnerability to developing dementia. In fact, a 
recent review suggests 35 that an incomplete understanding of the interactions between drugs 
and genotype that are not considered for in clinical trials might explain some of the 
controversial results of HRT trials on cognition. Further, most clinical trials were not 
specifically designed to measure cognitive performance as a primary outcome measure. 12 
Hence it is not clear whether they were statistically powered enough to detect actual cognitive 
effects. In addition, most studies used clinical cognitive tests which are meant to detect gross 
effects, hence more subtle effects may have gone undetected. This results in most trials 
showing so-called ‘ceiling effects’ (i.e. participants perform close to 100% correct) and thus, 
subtle differences between groups can be hard to measure. Future trials are clearly needed to 
investigate a more mechanistic role of hormonal levels and cognitive changes pre- and post-
menopause to potentially corroborate the observational findings (or ‘critical window’ 
hypothesis). 
 
 
Dementia and menopause 
There is currently a large body of studies and public health data showing that incidences of 
dementia are higher in women than in men. 36 Until recently, the difference in incidence rates 
were regarded as a collateral effect of women living on average longer than men. 2 This 
theory is consistent with age being a major risk factor for dementia and hence, aged women 
suffer significant cognitive decline and thus a higher incidence rate of dementia.  3,4 However, 
more recent evidence highlights that even when controlling for survival rates in men and 
women, the increased risk for women persists. 8 Moreover, from a diagnostic perspective, 
attentional and mnemonic changes in cognition that are primarily reported in post-
menopausal women are also considered key clinical symptomology in the diagnostic work-up 
of patients presenting at dementia clinics. 12 Clearly, this evidence raises the question as to 
whether hormonal changes during the menopause potentially trigger a pathophysiological 
cascade for Alzheimer’s disease (AD).  9 
 
Already, this notion has recently found strong support by a large meta-analysis of data from 
over 50,000 women across multiple studies. 37 The study reported that women have a 
particularly high risk of developing dementia directly in the years following the menopause 
compared to men (< 70 years), whereas this sex difference in dementia risk dissipates after 70 
years of age, by which time the risk between men and women was similar. This non-linear 
relationship between the sexes nicely dovetails with the ‘critical window’ hypothesis in 
females, highlighting that risk for dementia might vary for women even in different 
postmenopausal stages, a notion that has potential treatment implications.   
 
Still, precisely how hormonal changes might affect the onset of dementia is still being 
established. Thus, it is necessary to firstly understand how the neuropathology of dementia 
develops in the brain in order to understand how menopause related hormonal and metabolic 
fluctuations might influence this process.  The pathophysiology of AD (which accounts for 
two-thirds of all dementia cases) is widely accepted to be caused by the accumulation of two 
insoluble neurotoxic proteins, amyloid beta plaques and neurofibrillary tau tangles. 12 There is 
a clear difference in the distribution of amyloid and tau within the brain however, with 
amyloid being mostly dispersed throughout all the brain, whereas tau specifically appears 
first in the medial temporal lobes before spreading to other cortical regions.  
 
Currently, research suggests that the confluence of amyloid and tau triggers the cascade for 
AD, particularly in the medial temporal lobe regions such as the entorhinal cortex and 
hippocampus. 38 In addition to the amyloid/tau pathophysiology, several other precipitating 
factors can act as seeds for the AD pathology, including neuroinflammatory processes and 
vascular related brain changes, which have been shown to increase the risk of dementia 
considerably. 12 
 
Several biological mechanisms can potentially be linked to menopausal hormone changes, 
cognitive impairment, and dementia onset. 13 For example, it has been shown that oestrogen 
improves synapse formation on dendritic spines in the hippocampus of oophorectomized rat. 
21 Thus, reduction in such hormonal induced neuroprotective factors might make the 
hippocampus – one of the first regions affected by dementia - more vulnerable towards 
dementia pathophysiology. Similarly, as mentioned above, oestrogen can improve cerebral 
blood flow and glucose metabolism, therefore increasing overall perfusion and potentially 
counteracting the formation of the microvascular lesion events in the brain which can 
precipitate dementia. Finally, and most importantly, oestrogen has been shown to reduce the 
deposition of amyloid beta in the brain, 39,40,41 therefore having a more direct impact on the 
actual pathophysiological processes for dementia.  
This then raises the question as to whether HRT, by increasing hormonal neuroprotective 
factors, might potentially serve as a protective treatment for the onset of AD, 42,43,44 similar to 
the prescription of statins to reduce cerebral vascular events. 45,46 Indeed, recent work 
comparing a large cohort of Oophorectomy women to referent women, showed a 20 - 40% 
reduction in relative risk of AD for women on HRT post-menopause 47,48,49. The risk 
discussed is relative as it is expressed as a percentage decrease correlated with undergoing an 
oophorectomy compared to a group that did not. 
However, it must be noted that other studies have reported an increased, rather than a 
decreased, risk of dementia in women treated by either oestrogen alone or oestrogen plus 
progestin at age 65 years or later. 50,51 These conflicting findings may be explained by an age-
dependent effect of oestrogen on the brain (akin to the ‘critical window’ hypothesis) for 
population-level studies which specifies treatment is required before the age of 60 years 12. 
Specifically, oestrogen may have a protective effect on the brain if given to women who 
undergo oophorectomy before reaching natural menopause, or if given in the perimenopausal 
and early postmenopausal years to women with natural menopause. 18 In contrast, oestrogen 
may indeed have deleterious effects on the brain if started many years after the onset of 
natural menopause, consistent with theories for a critical age window for neuroprotection 
against dementia in women. Clearly, this needs to be confirmed in future studies and trials, as 
it has potentially major implications for prevention in women at high risk of developing 
dementia, as well as the overall prevalence of dementia worldwide.  
The importance of the hormone especially in young women can also be recognised through a 
series of pregnancy studies. For example, Paola Gilsanz 49 (retrieved from Fox et al., 2018 52) 
supported the notion that increased oestrogen levels (via reproductive time span and 
pregnancies) throughout the lifespan, acts as a protective factor. However, the lack of 
consistent evidence for the effectiveness of HRT in younger vs older individuals suggests the 
more carefully controlled HRT trials are needed in future to truly establish if HRT started at an 
earlier age is a preventative measure for dementia.  
 
Finally, there is sufficient evidence to suggest that the role of genetic information should be 
considered when looking at the menopause-dementia link, thereby increasing the complexity 
of this relationship. 35,53 The main recessive genetic risk for dementia is the apolipoprotein 
epsilon 4 allele (APOE ε4), with heterozygous and homozygous carriers of the APOE ε4 
genotype harbouring a 4-fold to 12-fold increase risk of AD, respectively. 27 In particular, 
several studies have shown that female APOE ε4 carriers in particular have a significantly 
increased risk for dementia. 5 Interestingly, the APOE genotype 54 is closely linked to 
oestrogen mechanisms, 36 in particular for the lipid metabolism that both pathways are 
involved in. Importantly, clinical trials have shown that HRT protective mechanisms towards 
cognitive decline interacts with APOE genotype. 12,53 More specifically, studies have shown 
that female APOE ε4 carriers, who are vulnerable to AD, might benefit from HRT to reduce 
cognitive decline and potentially the onset of dementia. 4,12  However, so far there have been 
very few menopause studies and trials specifically for APOE genotyped women to explore 
this relationship, in particular towards the ‘critical window’ hypothesis. 27 
 
Summary & outlook 
Taken together, there is increasing evidence for not only a correlational, but also, a causal 
link between menopausal hormone changes and cognition as well as dementia, which has so 
far been under-explored in the literature. Despite the exciting findings discussed, it emerges 
that there is complex interaction between menopausal stages, HRT and genetic status (in 
particular for the APOE genotype) which appears to underlie cognitive deficits and 
potentially the onset of incipient dementia. In particular, the specific biological mechanisms 
which link oestrogen to cognitive changes and incipient dementia requires further 
investigation. In this regard, the impact of genetic risk factors, such as APOE or oestrogen 
receptors encoded by ESR1/2 genes, seem to be critical to our understanding of the risk 
profile of women for developing dementia across menopausal stages. Delineating those 
contributions might help identify women who are at a higher risk for dementia post-
menopause, based on their genotype status. This would enable the designing of much more 
targeted longitudinal and interventional studies for such women, who are potentially at the 
highest risk of cognitive decline and dementia. In turn, this might also reduce the admixture 
of women in clinical trials to increase the statistical power for interventions and reduce the 
outcome variability. Furthermore, on the cognitive testing side, it is recommended that a 
more systematic approach be adopted for testing cognitive performance in menopausal 
women objectively. In particular, more detailed and specific tests to detect potentially 
incipient dementia processes would be beneficial, as currently most studies and trials use 
crude cognitive screening tests. Of relevance in this regard might be novel, more dementia 
pathology specific tests in spatial navigation, which have been shown to be related to 
entorhinal cortex integrity and underlying amyloid/tau pathology. 38 This would allow the 
delineation of more general cognitive effects of menopausal hormonal changes from 
dementia specific ones, again informing future clinical trials. Finally, the identification of 
such specific menopausal phenotypic and genotypic changes would allow a more 
personalised approach to identify women ‘at-high-risk’ of developing dementia, which in turn 
would allow earlier treatment with a potential to alleviate or even delay the onset of the 
disease.  
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